Post-pandemic shifts in pediatric respiratory pathogens and co-infection dynamics in Xi'an and surrounding areas: a large-scale retrospective study from 2021 to 2025

西安及周边地区儿童呼吸道病原体和合并感染动态的后疫情时代变化:一项2021年至2025年的大规模回顾性研究

阅读:2

Abstract

BACKGROUND AND OBJECTIVE: The COVID-19 pandemic and subsequent changes in public health policies have profoundly altered respiratory pathogen circulation patterns. This study aimed to characterize pathogen distribution, temporal trends, and co-infection dynamics among pediatric patients with respiratory tract infection (RTI) across epidemic and post-epidemic periods in northwest China. METHODS: We retrospectively analyzed 37,678 hospitalized pediatric RTI cases at Xi’an Children’s Hospital from July 2021 to April 2025. Multiplex reverse transcription PCR with capillary electrophoresis was used to detect 13 common respiratory pathogens. We compared pathogen prevalence and co-infection rates between the epidemic (2021–2022) and post-epidemic (2023–2025) periods. Multivariate logistic regression and co-infection network visualization were used to identify risk factors and interaction patterns. RESULTS: Among all cases, 60.6% tested positive for at least one pathogen, with human rhinovirus (HRV, 11.60%), Mycoplasma pneumoniae (Mp, 9.78%), and human respiratory syncytial virus (HRSV, 8.66%) most frequently detected. Post-epidemic periods saw significant increases in Mp and HRSV. Specifically, Mp increased from 4.35% to 11.21%, and HRSV from 5.01% to 9.62%. The proportion of co-infections increased from 4.05% to 11.55% (p < 0.001), with HRV and Mp being the predominant pathogens in co-infections. Co-infection risk was significantly higher in children aged 0–12 years and during the post-epidemic period. Co-infection peaks occurred consistently in late autumn. CONCLUSION: This large-scale study reveals a substantial post-pandemic resurgence of Mp, HRSV, and co-infections among children in northwest China. HRV played a central role in co-infection networks. The findings highlight the importance of enhancing surveillance, developing preparedness frameworks, and specifically addressing pediatric co-infection dynamics. CLINICAL TRIAL NUMBER: Not applicable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-025-12128-2.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。